FKBP5 Gene Expression Predicts Antidepressant Treatment Outcome in Depression
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Adverse experiences and chronic stress are well-known risk factors for the development of major depression, and an impaired stress response regulation is frequently observed in acute depression. Impaired glucocorticoid receptor (GR) signalling plays an important role in these alterations, and a restoration of GR signalling appears to be a prerequisite of successful antidepressant treatment. Variants in genes of the stress response regulation contribute to the vulnerability to depression in traumatized subjects. Consistent findings point to an important role of FKBP5, the gene expressing FK506-binding protein 51 (FKBP51), which is a strong inhibitor of the GR, and thus, an important regulator of the stress response. We investigated the role of FKBP5 and FKB51 expression with respect to stress response regulation and antidepressant treatment outcome in depressed patients. This study included 297 inpatients, who participated in the Munich Antidepressant Response Signature (MARS) project and were treated for acute depression. In this open-label study, patients received antidepressant treatment according to the attending doctor’s choice. In addition to the FKBP5 genotype, changes in blood FKBP51 expression during antidepressant treatment were analyzed using RT-PCR and ZeptoMARKTM reverse phase protein microarray (RPPM). Stress response regulation was evaluated in a subgroup of patients using the combined dexamethasone (dex)/corticotropin releasing hormone (CRH) test. As expected, increased FKBP51 expression was associated with an impaired stress response regulation at baseline and after six weeks was accompanied by an elevated cortisol response to the combined dex/CRH test. Further, we demonstrated an active involvement of FKBP51 in antidepressant treatment outcome. While patients responding to antidepressant treatment had a pronounced reduction of FKBP5 gene and FKBP51 protein expression, increasing expression levels were observed in nonresponders. This effect was moderated by the genotype of the FKBP5 single nucleotide polymorphism (SNP) rs1360780, with carriers of the minor allele showing the most pronounced association. Our findings demonstrate that FKBP5 and, specifically, its expression product FKBP51 are important modulators of antidepressant treatment outcome, pointing to a new, promising target for future antidepressant drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recently, an increased FKBP5 mRNA expression was associated with HPA axis dysfunction and worse response to antidepressants in patients suffering from MDD [121].”
From The HPA Axis as Target for Depression (2024) · cites this paper as [121]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190 · cited 1×
“FKBP5 RNA quantification was calculated against the activity of four housekeeping genes (beta-glucuronidase, hypoxanthine–guanine phosphoribosyltransferase 1, phospholipase A2, and TATA-box binding protein) using the delta cycle threshold (CT) method [43] for each housekeeping gene.”
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Stress and the brain: from adaptation to disease
de Kloet, E. R., Joëls, M., & Holsboer, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1683 · Cited by 4,621 · cited 1×
“The glucocorticoid receptor (GR) complex plays a critical role in HPA axis regulation [9,15] as impaired GR signalling results in an attenuated negative-feedback inhibition of the HPA axis, finally leading to chronically elevated glucocorticoid levels.”
Self-citationHammen, C. (2005) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.1.102803.143938 · Cited by 2,979 · cited 1×
“Specifically, early adverse life experience has been frequently identified as an important environmental risk factor for adult depression [6,7], and severe and/or long-lasting stressors can trigger new disease episodes in vulnerable individuals [6,8].”
The Epidemiology of Depression Across Cultures
Kessler, R. C., & Bromet, E. J. (2013) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-031912-114409 · Cited by 2,657
Causal Relationship Between Stressful Life Events and the Onset of Major Depression
Kendler, K. S., Karkowski, L. M., & Prescott, C. A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.837 · Cited by 2,566 · cited 1×
“Specifically, early adverse life experience has been frequently identified as an important environmental risk factor for adult depression [6,7], and severe and/or long-lasting stressors can trigger new disease episodes in vulnerable individuals [6,8].”
The Corticosteroid Receptor Hypothesis of Depression
Holsboer, F. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00159-7 · Cited by 2,181 · cited 2×
“In fact, acute depression is frequently accompanied by a disturbed stress response regulation, which is indicated, for instance, by elevated endocrine responses to pharmacological challenges of the hypothalamus–pituitary–adrenocortical (HPA) axis, the major stress regulation system [9].”
Self-citationKendler, K. S., Prescott, C. A., Myers, J., & Neale, M. C. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.9.929 · Cited by 1,868 · cited 2×
“As depression is a multifactorial disorder, genetic and environmental factors also contribute substantially to depression risk and outcome development [4].”
The link between childhood trauma and depression: insights from HPA axis studies in humans
Heim, C., Newport, D. J., Mletzko, T., Miller, A. H., & Nemeroff, C. B. (2008) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.03.008 · Cited by 1,704 · cited 1×
“Specifically, early adverse life experience has been frequently identified as an important environmental risk factor for adult depression [6,7], and severe and/or long-lasting stressors can trigger new disease episodes in vulnerable individuals [6,8].”
Allele-specific FKBP5 DNA demethylation mediates gene–childhood trauma interactions
Klengel, T., Mehta, D., Anacker, C., Rex-Haffner, M., Pruessner, J. C., Pariante, C. M., Pace, T. W. W., Mercer, K. B., Mayberg, H. S., Bradley, B., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3275 · Cited by 1,447 · cited 1×
“It is assumed that the rs1360780 risk variant, despite being intronic, might be associated with an increased glucocorticoid-related induction of FKBP5 RNA expression [30], presumably, as a result of environmentally triggered changes in DNA demethylation of cytosine-phosphate-guanine (CpG) dinucleotide rich regions in…”
Self-citationBinder, E. B. (2008) · JAMA · doi:10.1001/jama.299.11.1291 · Cited by 1,362 · cited 1×
“The same genetic variations increased the risk for adult depression [22,23] and for post-traumatic stress disorder [22,24] in individuals reporting early exposure to an adverse environment.”
Risk for recurrence in depression
Burcusa, S. L., & Iacono, W. G. (2007) · Clinical Psychology Review · doi:10.1016/j.cpr.2007.02.005 · Cited by 1,023 · cited 1×
“Depression is also a highly recurrent disorder with more than half of first-episode patients experiencing a second episode or more [2].”
Binder, E. B., Salyakina, D., Lichtner, P., Wochnik, G. M., Ising, M., Pütz, B., Papiol, S., Seaman, S., Lucae, S., Kohli, M. A., et al. (2004) · Nature Genetics · doi:10.1038/ng1479 · Cited by 977 · cited 1×
“It is assumed that the rs1360780 risk variant, despite being intronic, might be associated with an increased glucocorticoid-related induction of FKBP5 RNA expression [30], presumably, as a result of environmentally triggered changes in DNA demethylation of cytosine-phosphate-guanine (CpG) dinucleotide rich regions in…”
Self-citationBinder, E. B. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.05.021 · Cited by 968 · cited 2×
“Genetic variations in the FKBP5 gene were shown to be associated with the regulation of the HPA axis, with increased depression recurrence and rapid antidepressant treatment response [20,21].”
The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders
Heuser, I., Yassouridis, A., & Holsboer, F. (1994) · Journal of Psychiatric Research · doi:10.1016/0022-3956(94)90017-5 · Cited by 662
Self-citationPsychiatric genetics: progress amid controversy
Burmeister, M., McInnis, M. G., & Zöllner, S. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2381 · Cited by 525 · cited 1×
“Indeed, twin and family studies suggest a 35–40% contribution of genetic factors to disease liability, while the remaining risk variance is best explained by individual environmental events and biographic circumstances [4,5].”
Cattaneo, A., Gennarelli, M., Uher, R., Breen, G., Farmer, A., Aitchison, K. J., Craig, I. W., Anacker, C., Zunsztain, P. A., McGuffin, P., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.191 · Cited by 436
Endicott, J. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780260100011 · Cited by 428
Zobel, A. W., Nickel, T., Sonntag, A., Uhr, M., Holsboer, F., & Ising, M. (2001) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00013-9 · Cited by 354 · cited 3×
“The combined dex/CRH test was conducted as previously described [14].”
Self-citationIsing, M., Horstmann, S., Kloiber, S., Lucae, S., Binder, E. B., Kern, N., Künzel, H. E., Pfennig, A., Uhr, M., & Holsboer, F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.039 · Cited by 341 · cited 2×
“In this study we investigated concomitant changes between HPA axis regulation, FKBP5 gene expression, and antidepressant treatment outcome, while previous studies on the role of the combined dex/CRH test documented that a normalized HPA axis regulation precedes antidepressant treatment outcome by several weeks [12] an…”
Self-citationVermeer, H., Hendriks-Stegeman, B. I., van der Burg, B., van Buul-Offers, S. C., & Jansen, M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020354 · Cited by 285 · cited 1×
“This is in agreement with previous findings, suggesting that peripheral FKBP5 RNA expression is induced by elevated glucocorticoid levels in patients with affective and anxiety disorders [20], which could also be confirmed in a human lymphoblastoid cell line model [29].”
The combined dexamethasone/CRH test as a potential surrogate marker in depression
Ising, M., Künzel, H. E., Binder, E. B., Nickel, T., Modell, S., & Holsboer, F. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.03.014 · Cited by 271 · cited 2×
“In addition, previous studies using the combined dex/CRH test reported homogenous effects of effective antidepressant treatments on HPA axis regulation [11], which presumably can also be expected for FKBP51.”
Self-citationA Comparison of Depression Rating Scales
Kearns, N. P., Cruickshank, C. A., McGuigan, K. J., Riley, S. A., Shaw, S. P., & Snaith, R. P. (1982) · British Journal of Psychiatry · doi:10.1192/bjp.141.1.45 · Cited by 271 · cited 1×
“Only patients with a baseline HAMD-21 score of 14 or higher were included, setting the lower threshold at a moderate depression severity [40,41], while most patients were suffering from severe depression as indicated by an average HAMD-21 baseline score of 26.”
Zimmermann, P., Brückl, T., Nocon, A., Pfister, H., Binder, E. B., Uhr, M., Lieb, R., Moffitt, T. E., Caspi, A., Holsboer, F., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111577 · Cited by 262 · cited 1×
“The same genetic variations increased the risk for adult depression [22,23] and for post-traumatic stress disorder [22,24] in individuals reporting early exposure to an adverse environment.”
Self-citationPawlak, M., Schick, E., Bopp, M. A., Schneider, M. J., Oroszlan, P., & Ehrat, M. (2002) · PROTEOMICS · doi:10.1002/1615-9861(200204)2:4<383::aid-prot383>3.0.co;2-e · Cited by 258 · cited 1×
“A ZeptoMARKTM reverse phase protein microarray (RPPM) platform (Zeptosens AG, Witteswil, Switzerland) was used for FKBP51 protein profiling following the manufacturer’s standard protocol [44] with array readout and quantification performed using the analysis software ZeptoVIEW 3.”
Chaperoning of Glucocorticoid Receptors
Pratt, W. B., Morishima, Y., Murphy, M., & Harrell, M. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-29717-0_5 · Cited by 245 · cited 1×
“The GR function is modulated by chaperone proteins forming a molecular complex that is required for proper ligand binding and receptor activation, as well as transcriptional regulation of the GR target genes [16,17].”
Wang, Q., Shelton, R. C., & Dwivedi, Y. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.08.066 · Cited by 201 · cited 1×
“The same genetic variations increased the risk for adult depression [22,23] and for post-traumatic stress disorder [22,24] in individuals reporting early exposure to an adverse environment.”
Hennings, J. M., Owashi, T., Binder, E. B., Horstmann, S., Menke, A., Kloiber, S., Dose, T., Wollweber, B., Spieler, D., Messer, T., et al. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.05.002 · Cited by 195 · cited 1×
“MARS is a naturalistic open-label longitudinal study conducted at the hospital of the Max Planck Institute of Psychiatry and collaborating hospitals in Southern Bavaria and Switzerland to identify predictors for antidepressant drug response and to identify subgroups of depressed patients with common pathology benefitt…”
Self-citationPharmacogenetics in major depression: A comprehensive meta-analysis
Niitsu, T., Fabbri, C., Bentini, F., & Serretti, A. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.05.011 · Cited by 190 · cited 1×
“Both studies investigating FKBP5 gene expression on antidepressant treatment outcome were conducted with relatively small patient samples and did not consider FKBP5 genotypes previously identified as associated with antidepressant treatment outcome [27].”
Gassen, N. C., Hartmann, J., Zschocke, J., Stepan, J., Hafner, K., Zellner, A., Kirmeier, T., Kollmannsberger, L., Wagner, K. V., Dedic, N., et al. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001755 · Cited by 177 · cited 1×
“These pathways include the glycogen synthase kinase-3 (GSK-3) beta pathway [32], autophagy [33], and the modulation of enzymes of the epigenetic machinery [34].”
Self-citationAppelhof, B. C., Huyser, J., Verweij, M., Brouwer, J. P., van Dyck, R., Fliers, E., Hoogendijk, W. J. G., Tijssen, J. G. P., Wiersinga, W. M., & Schene, A. H. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.008 · Cited by 154 · cited 1×
“Restored HPA axis regulation after successful treatment as indicated by a normalized cortisol response to the combined dex/CRH test is associated with sustained remission [11,12], while the recurrence of an impaired HPA axis regulation predicts increased relapse risk in remitted patients [13,14].”
Hsp90 and FKBP51: complex regulators of psychiatric diseases
Criado-Marrero, M., Rein, T., Binder, E. B., Porter, J. T., Koren, J., & Blair, L. J. (2018) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2016.0532 · Cited by 146 · cited 1×
“The GR function is modulated by chaperone proteins forming a molecular complex that is required for proper ligand binding and receptor activation, as well as transcriptional regulation of the GR target genes [16,17].”
Pharmacological Inhibition of the Psychiatric Risk Factor FKBP51 Has Anxiolytic Properties
Hartmann, J., Wagner, K. V., Gaali, S., Kirschner, A., Kozany, C., Ruhter, G., Dedic, N., Hausl, A. S., Hoeijmakers, L., Westerholz, S., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.4024-14.2015 · Cited by 109 · cited 1×
“Nevertheless, FKBP51 inhibitors are currently in development as potential new antidepressant drugs, with early promising findings indicating the anxiolytic and potentially antidepressant effects of such compounds [36,37].”
Self-citationGassen, N. C., Fries, G. R., Zannas, A. S., Hartmann, J., Zschocke, J., Hafner, K., Carrillo-Roa, T., Steinbacher, J., Preißinger, S. N., Hoeijmakers, L., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aac7695 · Cited by 107 · cited 1×
“These pathways include the glycogen synthase kinase-3 (GSK-3) beta pathway [32], autophagy [33], and the modulation of enzymes of the epigenetic machinery [34].”
Self-citationEwald, E. R., Wand, G. S., Seifuddin, F., Yang, X., Tamashiro, K. L., Potash, J. B., Zandi, P., & Lee, R. S. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.03.003 · Cited by 105 · cited 1×
“While variations in the gene expression pattern between different specimens or tissues cannot be ruled out, there is evidence that glucocorticoid exposure regulates FKBP51 expression via changes in DNA methylation in blood cells and in the brain in a very similar manner [38].”
Fabbri, C., Hosak, L., Mössner, R., Giegling, I., Mandelli, L., Bellivier, F., Claes, S., Collier, D. A., Corrales, A., Delisi, L. E., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2016.1208843 · Cited by 81 · cited 3×
“Genetic variations in the FKBP5 gene were shown to be associated with the regulation of the HPA axis, with increased depression recurrence and rapid antidepressant treatment response [20,21].”
Galigniana, N. M., Ballmer, L. T., Toneatto, J., Erlejman, A. G., Lagadari, M., & Galigniana, M. D. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07775.x · Cited by 77 · cited 1×
“While HSP90 is essential for GR steroid binding, the cochaperone FK506-binding protein 51 (FKBP51), coded by the FKBP5 gene, exhibits inhibitory effects by reducing the binding affinity of the GR [18,19].”
Squirrel Monkey Immunophilin FKBP51 Is a Potent Inhibitor of Glucocorticoid Receptor Binding1
Denny, W. B., Valentine, D. L., Reynolds, P. D., Smith, D. F., & Scammell, J. G. (2000) · Endocrinology · doi:10.1210/en.141.11.4107 · Cited by 66 · cited 1×
“While HSP90 is essential for GR steroid binding, the cochaperone FK506-binding protein 51 (FKBP51), coded by the FKBP5 gene, exhibits inhibitory effects by reducing the binding affinity of the GR [18,19].”
Rein, T. (2016) · BioEssays · doi:10.1002/bies.201600050 · Cited by 64 · cited 1×
“While these findings suggest the potential of a direct causal link between altered FKBP51 and antidepressant action, the exact mechanisms are yet to be elucidated [35].”
FKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications
Gassen, N. C., Hartmann, J., Zannas, A. S., Kretzschmar, A., Zschocke, J., Maccarrone, G., Hafner, K., Zellner, A., Kollmannsberger, L. K., Wagner, K. V., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.38 · Cited by 62 · cited 1×
“These pathways include the glycogen synthase kinase-3 (GSK-3) beta pathway [32], autophagy [33], and the modulation of enzymes of the epigenetic machinery [34].”
Self-citationMalmström, J. A., Larsen, K. S., Hansson, L., Löfdahl, C., Jensen, O. N., Marko‐Varga, G., & Westergren‐Thorsson, G. (2002) · PROTEOMICS · doi:10.1002/1615-9861(200204)2:4<394::aid-prot394>3.0.co;2-6 · Cited by 48
Sabbagh, J. J., Cordova, R. A., Zheng, D., Criado-Marrero, M., Lemus, A., Li, P., Baker, J. D., Nordhues, B. A., Darling, A. L., Martinez-Licha, C., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00454 · Cited by 48 · cited 1×
“Nevertheless, FKBP51 inhibitors are currently in development as potential new antidepressant drugs, with early promising findings indicating the anxiolytic and potentially antidepressant effects of such compounds [36,37].”
Banach, E., Szczepankiewicz, A., Leszczyńska-Rodziewicz, A., Pawlak, J., Dmitrzak‐Węglarz, M., Zaremba, D., & Hauser, J. (2017) · Psychiatria Polska · doi:10.12740/pp/76329 · Cited by 14 · cited 3×
“A recent study did not find changes in leukocyte FKBP5 RNA expression in female patients with major depression (N = 30), who were treated for eight weeks with the SSRI, sertraline, or with the selective serotonin noradrenalin reuptake inhibitor (SNRI), venlafaxine [26].”
Influential
Cited by
The HPA Axis as Target for Depression
Menke, A. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230811141557 · Cited by 131
“Recently, an increased FKBP5 mRNA expression was associated with HPA axis dysfunction and worse response to antide-pressants in patients suffering from MDD [121].”
BackgroundPharmacogenomics: A road ahead for precision medicine in psychiatry
Pardiñas, A. F., Owen, M. J., & Walters, J. (2021) · Neuron · doi:10.1016/j.neuron.2021.09.011 · Cited by 90
Fu, C., Chen, Z., Chen, M., Chen, G., Huang, Q., Yang, X., Yin, H., Chen, L., Zhang, W., Lin, H., et al. (2021) · npj Biofilms and Microbiomes · doi:10.1038/s41522-021-00231-6 · Cited by 66
Biomarkers in Child and Adolescent Depression
Zwolińska, W., Dmitrzak‐Węglarz, M., & Słopień, A. (2021) · Child Psychiatry & Human Development · doi:10.1007/s10578-021-01246-y · Cited by 77
Malekpour, M., Shekouh, D., Safavinia, M. E., Shiralipour, S., Jalouli, M., Mortezanejad, S., Azarpira, N., & Ebrahimi, N. D. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1182345 · Cited by 85
Metadata
- Authors
- Ising, M., Maccarrone, G., Brückl, T., Scheuer, S., Hennings, J., Holsboer, F., Turck, C. W., Uhr, M., & Lucae, S.
- Affiliations
- Max Planck Institute of Psychiatry (DE)
- kbo-Isar-Amper Clinical Center Munich East, 85540 Munich, Germany
- HolsboerMaschmeyer NeuroChemie (Germany) (DE)
- Corresponding author
- Ising, Marcus
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-01-23
- Volume
- 20
- Issue
- 3
- Pages
- 485
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6387218
- OpenAlex
- W2914861780
- Cited by
- 60
- References
- 43
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 8 · 2023: 12 · 2022: 5 · 2021: 18 · 2020: 5 · 2019: 2
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Bundesministerium für Bildung und Forschung (01ES0811)
- Topics
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- FKBP5, FKBP51, antidepressant treatment outcome, depression, stress response regulation, cortisol response, dexamethasone/corticotropin-releasing hormone test, rs1360780, gene expression, acute depression
- MeSH terms
- Tacrolimus Binding Protein 5, Adult, Alleles, Antidepressive Agents, Depression, Female, Genotype, Humans, Hypothalamo-Hypophyseal System, Longitudinal Studies, Male, Middle Aged, Pituitary-Adrenal System, Prognosis, Time Factors, Biomarkers, Gene Expression, Treatment Outcome, Tacrolimus Binding Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.